136 filings
8-K
ANVS
Annovis Bio Inc
5 Jun 24
Regulation FD Disclosure
4:32pm
8-K
ANVS
Annovis Bio Inc
21 May 24
Annovis Announces New Publication in a Peer-Reviewed Journal
4:05pm
8-K
ANVS
Annovis Bio Inc
13 May 24
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
4:05pm
10-Q
2024 Q1
ANVS
Annovis Bio Inc
Quarterly report
10 May 24
5:11pm
8-K
ANVS
Annovis Bio Inc
9 May 24
Annovis Announces Unblinding of the Buntanetap Phase Iii Data In Parkinson’s Disease
4:03pm
DEFA14A
xlj44u3hu bkh5544dit
6 May 24
Additional proxy soliciting materials
5:12pm
8-K
u6byagg8u9r
6 May 24
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
5:11pm
8-K
02bomk ege8
2 May 24
Other Events
4:01pm
8-K
ybffkyon2ae
1 May 24
Departure of Directors or Certain Officers
5:18pm
424B5
l9uz99edk
1 May 24
Prospectus supplement for primary offering
4:50pm
ARS
rwosmqf 54al
29 Apr 24
Annual report to shareholders
5:14pm
DEFA14A
i2z6j1
29 Apr 24
Additional proxy soliciting materials
5:12pm
8-K
ouobnh10ibpm
26 Apr 24
Entry into a Material Definitive Agreement
8:14am
8-K
eb4 o5k6vpveij
22 Mar 24
Other Events
5:24pm
8-K
0vg584 m6
21 Mar 24
Entry into a Material Definitive Agreement
5:23pm
8-K
9btpk33p94ptpx5ai
20 Mar 24
Annovis Bio Provides Data Announcement Update for the Phase Ii/iii Study of Buntanetap In Alzheimer’s Disease
4:43pm
8-K
t20du
19 Mar 24
Other Events
9:20pm
424B5
aue67epy3
18 Mar 24
Prospectus supplement for primary offering
10:00pm